ライフサイエンスコーパス: congestive

1 ally enable assessment of necroinflammatory, congestive, and fibrotic processes of chronic liver dise

2 Only congestive cardiac failure (CCF) was an independent pred

3 ne [1%]), bone pain (one [1%] vs four [2%]), congestive cardiac failure (four [2%] vs two [1%]), myoc

4 ion group (sepsis [n=2], septic shock [n=1], congestive cardiac failure [n=1], and unknown cause [n=1

5 t is currently licensed for hypertension and congestive cardiac failure, showed neuroprotective and m

6 0-day death or combined endpoint (defined as congestive heart failure >/= New York Heart Association

7 of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), bot

8 ; HR: 1.18; 95% CI: 1.04 to 1.34; p = 0.01), congestive heart failure (107 events; HR: 1.25; 95% CI:

9 lized for acute myocardial infarction (19%), congestive heart failure (25%), pneumonia (30%), and con

10 04), stroke (2.43% vs. 1.93%; p = 0.05), and congestive heart failure (3.75% vs. 2.25%; p < 0.0001) t

11 ents, and the most common cause of death was congestive heart failure (37%).

12 -20.4%), cardiac dysrhythmias (21.7%-29.0%), congestive heart failure (40.7%-56.1%), acute (5.9%-20.1

13 r dysfunction, but blacks had more prevalent congestive heart failure (43% versus 34%; P=0.04) and le

14 ry disease (26.6 to 12.6% of admissions) and congestive heart failure (8.5 to 5.4% of admissions).

15 OR: 0.36; 95% CI: 0.31 to 0.42; p < 0.001), congestive heart failure (adjusted OR: 0.82; 95% CI: 0.7

16 associated with greater risk of adjudicated congestive heart failure (CHF) and atherosclerotic event

17 mplication of many chronic diseases, such as congestive heart failure (CHF) and chronic kidney diseas

18 Secondary analyses assessed incident congestive heart failure (CHF) and mortality with coexis

19 Congestive heart failure (CHF) causes atrial fibrotic re

20 Congestive heart failure (CHF) is a leading cause of mor

21 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

22 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

23 valence of mental stress-induced ischemia in congestive heart failure (CHF) patients is unknown.

24 HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfe

25 -myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-c

26 all episodes of myocardial infarction (MI), congestive heart failure (CHF), abdominal aortic aneurys

27 Cardiac death, severe congestive heart failure (CHF), and confirmed significan

28 admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD were obt

29 In congestive heart failure (CHF), carotid body (CB) chemor

30 echolamine stimulation during development of congestive heart failure (CHF), chronic activation of Gs

31 years included panel-reactive antibody >10%, congestive heart failure (CHF), delayed graft function,

32 ital arrhythmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of stay, preterm

33 m from cardiology, neurology and psychiatry: Congestive Heart Failure (CHF), Major Depression Disorde

34 patients without cirrhosis and patients with congestive heart failure (CHF), matched for age, sex, an

35 rate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease

36 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

37 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

38 hospitalization or emergency room visit for congestive heart failure (CHF), outpatient diagnosis of

39 on (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic kidney d

40 ions (PVCs) are a modifiable risk factor for congestive heart failure (CHF).

41 ation), Kussmaul sign, has been described in congestive heart failure (CHF).

42 n-ischemic cardiomyopathy without history of congestive heart failure (CHF).

43 n postulated to improve functional status in congestive heart failure (CHF).

44 n patients with atrial fibrillation (AF) and congestive heart failure (CHF).

45 associated with cardiotoxicity manifested as congestive heart failure (CHF).

46 lation (AF), myocardial infarction (MI), and congestive heart failure (CHF).

47 astolic dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic f

48 event the rare, but serious, complication of congestive heart failure (HF) associated with anthracycl

49 infarction (HR, 0.77; 95% CI, 0.54-1.10) and congestive heart failure (HR, 1.22; 95% CI, 0.84-1.82) d

50 6; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72),

51 Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-

52 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to

53 tient with a history of atrial fibrillation, congestive heart failure (NYHA II/III), stable coronary

54 sease (odds ratio, 1.22; 95% CI, 1.11-1.34), congestive heart failure (odds ratio, 1.14; 95% CI, 1.08

55 llation (OR, 0.82; CI, 0.70-0.95; P = 0.01), congestive heart failure (OR, 0.73; CI, 0.60-0.88; P < 0

56 22; 95% CI, 1.00-1.48; P = .045), history of congestive heart failure (OR, 1.25; 95% CI, 1.12-1.39; P

57 liver disease (OR, 1.57; 95% CI, 1.39-1.77); congestive heart failure (OR, 1.49; 95% CI, 1.38-1.61);

58 Congestive heart failure (OR, 1.7; 95% CI, 1.3-2.2), car

59 (P </= 0.04), heart attack (P </= 0.01), and congestive heart failure (P </= 0.02), but not with stro

60 P<0.001), pulmonary hypertension (P<0.0001), congestive heart failure (P=0.0008), and liver disease (

61 gnosis at index AKI hospitalization included congestive heart failure (primary diagnosis), decompensa

62 t disease (RR, 4.31; 95% CI, 3.38-5.49), and congestive heart failure (RR, 2.05; 95% CI, 1.29-3.25).

63 Evaluate Challenging Responses to Therapy in Congestive Heart Failure (SECRET of CHF) trials.

64 .0; 95% confidence interval [CI], 4.8-13.5), congestive heart failure (unadjusted HR, 3.2; 95% CI, 1.

65 6-3.69), high-risk surgery 2.70 (2.46-2.96), congestive heart failure 2.65 (2.29-3.06), cerebrovascul

66 (Atrial Fibrillation and Congestive Heart Failure [AF-CHF]; NCT88597077).

67 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).

68 A composite outcome of death and congestive heart failure admission was recorded.

69 A composite outcome of death and congestive heart failure admission was recorded.

70 et the composite end point (48 deaths and 19 congestive heart failure admissions, 2.5% 30-day deaths)

71 s were more likely to have had AKI, multiple congestive heart failure admissions, and other hospitali

72 revention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarcti

73 were to identify correlates of mortality and congestive heart failure after aortic valve replacement

74 relates of the composite outcome of death or congestive heart failure after AVR.

75 to the emergency department with symptoms of congestive heart failure and a 1-week history of chest p

76 Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication

77 radation of cardiac control in patients with congestive heart failure and a more degradation in criti

78 ing hospitalization for sepsis compared with congestive heart failure and acute myocardial infarction

79 readmissions following sepsis compared with congestive heart failure and acute myocardial infarction

80 ative to other high-risk conditions, such as congestive heart failure and acute myocardial infarction

81 ficant therapeutic value in the treatment of congestive heart failure and arrhythmia.

82 on diagnoses at the time of readmission were congestive heart failure and arrhythmia.

83 high rates of readmission, predominantly for congestive heart failure and arrhythmia.

84 of left ventricular failure in patients with congestive heart failure and bronchoconstriction.

85 arison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [ST

86 re embryonic day 9; TnT/Isl1-Cre) results in congestive heart failure and death by embryonic day 11.5

87 left ventricular (LV) decline, resulting in congestive heart failure and death.

88 g dialysis patients, warfarin users had more congestive heart failure and diabetes mellitus, but fewe

89 h as sleep-disordered breathing with apnoea, congestive heart failure and essential hypertension.

90 also compared for patients with a history of congestive heart failure and for patients aged >/=80.

91 ,946), CTDN was superior to HCTZ in reducing congestive heart failure and in reducing all CVEs: perce

92 requent; however, exacerbation of asthma and congestive heart failure and one fatal cerebral hemorrha

93 and (2) patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

94 We analyzed the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

95 t Failure Score, ESCAPE [Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

96 portions of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

97 In phase 3, 19 patients with congestive heart failure and pulmonary hypertension cons

98 ase 2, 32 participants (including those with congestive heart failure and pulmonary hypertension) use

99 ment of the pathophysiology of congestion in congestive heart failure and the methods by which we det

100 re likely to have had a primary diagnosis of congestive heart failure at the time of index admission,

101 pitalized for acute myocardial infarction or congestive heart failure but not among those hospitalize

102 f acute myocardial infarction cases, 1.7% of congestive heart failure cases, and 5.8% of stroke cases

103 Symptomatic congestive heart failure defined as New York Heart Assoc

104 One patient with congestive heart failure died from refractory left ventr

105 A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchron

106 In CHS, 997 congestive heart failure events occurred during 39 238 p

107 ing 39 238 person-years; in ARIC, 330 events congestive heart failure events occurred during 64 438 p

108 ar events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or ca

109 Multivariate analysis showed that congestive heart failure greater than or equal to New Yo

110 The top hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and

111 sympathetic overstimulation in patients with congestive heart failure have a negative inotropic effec

112 About one-half of the patients with congestive heart failure have preserved left ventricular

113 earts and paroxysmal AF, although those with congestive heart failure have the greatest potential ben

114 .05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failure HR 1.57 (1.39-1.78), depression

115 etary sources, were associated with incident congestive heart failure in 2 independent cohorts, sugge

116 ctive biomarkers of exposure, with incidence congestive heart failure in 2 independent cohorts: 3694

117 ession of, for instance, sleep disorders and congestive heart failure in diabetic patients.

118 ac events at 90 days with significantly less congestive heart failure in the intracoronary abciximab

119 of chronic obstructive pulmonary disease or congestive heart failure in univariate analyses.

120 ting as asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patient

121 Congestive heart failure is one of the leading causes of

122 relatively early stages, the abrupt onset of congestive heart failure is uncommon and should raise su

123 In this population, congestive heart failure is well recognised as a progres

124 l in which weight, severe liver disease, and congestive heart failure most affected fentanyl concentr

125 cardiac end point was defined as symptomatic congestive heart failure of New York Heart Association c

126 ction, stroke, gastrointestinal bleeding, or congestive heart failure or a Diagnosis Related Group cl

127 thin the categories of sudden death, cancer, congestive heart failure or chronic lung disease, and fr

128 in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.

129 The risk of new MI, being admitted with congestive heart failure or death, increased with increa

130 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than

131 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than

132 Among high-risk subjects, those with congestive heart failure or ischemic stroke as their ind

133 reast cancer, except for those with clinical congestive heart failure or significantly compromised le

134 rmed HCM presented with rapid development of congestive heart failure over 6 months, in sharp contras

135 etermine if nesiritide increases diuresis in congestive heart failure patients.

136 comitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial da

137 ese steps using a hypothetical example for a congestive heart failure postdischarge clinic.

138 ard Medical therapy in Elderly patients with Congestive Heart Failure randomized 499 patients with HF

139 er the inclusion of an SES measure in 30-day congestive heart failure readmission models changed hosp

140 nute walk test (6MWT) independently predicts congestive heart failure severity, death, and heart fail

141 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS) and Study to Ev

142 A multivariable model-including angina, congestive heart failure symptoms, shockable arrest rhyt

143 cy department visits for asthma/wheezing and congestive heart failure than PM2.5.

144 ior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates

145 eing completely asymptomatic; to features of congestive heart failure to vaginal bleeding which may a

146 the Vasodilation in the Management of Acute Congestive Heart Failure trial.

147 Congestive heart failure typically arises from cardiac m

148 Current pathophysiological models of congestive heart failure unsatisfactorily explain the de

149 of myocardial infarction, stroke, or severe congestive heart failure using the National Health and N

150 visits with 17alpha(H),21beta(H)-hopane and congestive heart failure visits with elemental carbon.

151 tio, 11.42 [95% CI, 10.93-11.93]; P < .001); congestive heart failure was a negative correlatefold (o

152 terval, 4.73-89.53; P=0.0001) and history of congestive heart failure was also significantly associat

153 t wave days, but risk of hospitalization for congestive heart failure was lower (P < .05).

154 death, documented stroke, and admission for congestive heart failure was recorded.

155 schemic attack, prior systemic embolism, and congestive heart failure were associated with more frequ

156 ty, age >/= 75 years, history of stroke, and congestive heart failure were found to be independent pr

157 articipants, but not seniors, and those with congestive heart failure were less likely to achieve a 2

158 rdial infarction, stroke, and progression to congestive heart failure were recorded.

159 on, target vessel revascularization, and new congestive heart failure within 6 months.

160 , chronic obstructive pulmonary disease, and congestive heart failure) by using the Cox proportional

161 f Mechanical Assistance for the Treatment of Congestive Heart Failure) study experience, readmissions

162 Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address

163 The AF-CHF (Atrial Fibrillation and Congestive Heart Failure) trial randomized 1,376 patient

164 med angina, silent MI, revascularization, or congestive heart failure).

165 resistance and severe cardiotoxicity (e.g., congestive heart failure).

166 adverse events (grade 2 fatigue and grade 4 congestive heart failure).

167 potension, bradycardia, bronchospasm, and/or congestive heart failure).

168 Those who survive MI can develop congestive heart failure, a chronic condition of inadequ

169 ascular events, and disease-specific events: congestive heart failure, acute myocardial infarction, a

170 er age, White race, coronary artery disease, congestive heart failure, alcoholism, proteinuria, reduc

171 ncidence of coronary artery disease, stroke, congestive heart failure, all-cause mortality, and cardi

172 s ago, are used to treat hypertension and/or congestive heart failure, although there are therapeutic

173 vent (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangre

174 0 million/yr for sepsis, $229 million/yr for congestive heart failure, and $142 million/yr for acute

175 22.9%; interquartile range, 19.2-26.6%) for congestive heart failure, and 3.6% to 40.8% (median, 17.

176 tes were 20.4%, 23.6%, and 17.7% for sepsis, congestive heart failure, and acute myocardial infarctio

177 litus, hypertension, cardiovascular disease, congestive heart failure, and advanced chronic kidney di

178 olic blood pressure, hypertension treatment, congestive heart failure, and age.

179 ents at risk for faster disease progression, congestive heart failure, and arrhythmia.

180 outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality.

181 ey role in the pathogenesis of hypertension, congestive heart failure, and chronic kidney disease.

182 ge, female sex, Medicare or State insurance, congestive heart failure, and chronic kidney disease.

183 nce of death, myocardial infarction, stroke, congestive heart failure, and fractures, were compared d

184 Older age, congestive heart failure, and greater left ventricular d

185 age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin,

186 l history included diabetes mellitus type 2, congestive heart failure, and hypertension.

187 FDCM and IDCM but for both groups older age, congestive heart failure, and increased left ventricular

188 ng age, male gender, pulmonary hypertension, congestive heart failure, and liver disease are risk fac

189 composite primary end point of death, shock, congestive heart failure, and reinfarction when compared

190 increased risk for death, cardiac death, and congestive heart failure, and subjects presenting PTF >/

191 strongly influenced by severe liver disease, congestive heart failure, and weight, factors that shoul

192 er secondary events including hip fractures, congestive heart failure, angina, falls, depression, cho

193 V outcomes including coronary heart disease, congestive heart failure, arrhythmias, and stroke.

194 dialysis duration, peritoneal dialysis, and congestive heart failure, but not diabetes mellitus.

195 he in-hospital composite end point of death, congestive heart failure, cardiogenic shock, and reinfar

196 older and were more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascula

197 percent of clopidogrel-treated patients with congestive heart failure, cholecystectomy, and lower per

198 scular disease, peripheral vascular disease, congestive heart failure, chronic obstructive pulmonary

199 PE that had no corresponding comorbidities, congestive heart failure, chronic pulmonary disease, coa

200 ary outcomes were hospitalization because of congestive heart failure, coronary heart disease, new on

201 um concentrations, as occur in patients with congestive heart failure, could activate the PKD1/HDAC5/

202 ardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke

203 rior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial

204 cute coronary syndrome, atrial fibrillation, congestive heart failure, DM 2, and smoking.

205 o clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age

206 dicting major bleeding compared with CHADS2 (congestive heart failure, hypertension, 75 years of age

207 transient ischemic attack) and CHA2DS2-VASc (congestive heart failure, hypertension, 75 years of age

208 Clinical schemas, such as the CHA2DS2-VASc (congestive heart failure, hypertension, age >/= 75 years

209 Median CHADS2 score (congestive heart failure, hypertension, age >/= 75 years

210 The CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

211 er PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years

212 After adjustment for the CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

213 CHA2DS2VASc scores (congestive heart failure, hypertension, age >/=75 years

214 oint on the stroke risk scheme CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

215 sk patients, i.e., with 0 or 1 CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

216 ith atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >/=75 years,

217 nd bleeding risks were assessed by using the congestive heart failure, hypertension, age >/=75 years,

218 over established risk stratification scores (congestive heart failure, hypertension, age >/=75 years,

219 ears, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age >/=75 years,

220 patient population with predominant CHADS2 (Congestive heart failure, Hypertension, Age >/=75 years,

221 African-American ethnicity to CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

222 h atrial fibrillation (AF) with a "low-risk" congestive heart failure, hypertension, age >/=75, diabe

223 erformance of ATRIA to that of CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

224 sk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

225 Patients with NVAF who had a CHADS2 (congestive heart failure, hypertension, age >75 years, d

226 in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or

227 Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

228 e in subjects with ESVEA and a CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

229 average age of 70+/-12 years, a mean CHADS2 (congestive heart failure, hypertension, age>75, diabetes

230 alvular atrial fibrillation (AF) and CHADS2 (congestive heart failure, hypertension, age, diabetes me

231 roke and bleeding risk were calculated using congestive heart failure, hypertension, age, diabetes me

232 with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial f

233 Among AF patients, age >/=75 years, congestive heart failure, hypertension, diabetes mellitu

234 risk factors (diabetes mellitus, history of congestive heart failure, hypertension, or age older tha

235 ted in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic neph

236 patients with cardiovascular disease such as congestive heart failure, ischemic heart disease, valvul

237 included young age, low weight, presence of congestive heart failure, lower left ventricular fractio

238 nate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death.

239 he primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of

240 ac respiratory failure, atrial fibrillation, congestive heart failure, myocardial infarction, and reo

241 athy, by characteristics such as low weight, congestive heart failure, or abnormal echocardiographic

242 9.8) and the combination end point of death, congestive heart failure, or cardiogenic shock at 90 day

243 Patients with preexisting diabetes mellitus, congestive heart failure, or chronic or acute renal fail

244 infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) seriou

245 eficiaries with acute myocardial infarction, congestive heart failure, or pneumonia, 30-day mortality

246 y revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed

247 Congestive heart failure, paraplegia, dyspnea at rest, a

248 contained 10 categorical variables including congestive heart failure, paraplegia, reoperation, dyspn

249 05 and 2011 for acute myocardial infarction, congestive heart failure, pneumonia, or conditions requi

250 dial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficienc

251 y mass index, noncardiac surgery, history of congestive heart failure, renal disease, existing airway

252 de prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract sym

253 us thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, ga

254 -salt diet, a model for hypertension-induced congestive heart failure, spermidine feeding reduced sys

255 llowed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic a

256 s also been linked to myocardial infarction, congestive heart failure, stroke, and diabetes mellitus

257 al infarction, coronary heart disease death, congestive heart failure, stroke, incident angina, or in

258 A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarcti

259 ical diagnoses (acute myocardial infarction, congestive heart failure, stroke, pneumonia, and chronic

260 kg and no history of severe liver disease or congestive heart failure, the final model, which perform

261 Among patients with congestive heart failure, the rate of occurrence of adve

262 For patients with a history of congestive heart failure, the respective rates were 22.8

263 ial infarction, or serious adverse events of congestive heart failure, unstable angina, or arrhythmia

264 he relative risk of coronary artery disease, congestive heart failure, valvular heart disease, perica

265 s, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and di

266 risk score PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic

267 substantial number of patients with advanced congestive heart failure, yet is poorly defined.

268 ent with pacemaker syndrome, and 1 developed congestive heart failure.

269 seases, such as ventricular fibrillation and congestive heart failure.

270 ass index, ejection fraction, and history of congestive heart failure.

271 ation are at an increased risk of developing congestive heart failure.

272 tant tool for the diagnosis and treatment of congestive heart failure.

273 chexia is a life threatening complication in congestive heart failure.

274 prematurity, sleep disordered breathing and congestive heart failure.

275 ated to the chronic conditions of asthma and congestive heart failure.

276 k between the abdomen, heart, and kidneys in congestive heart failure.

277 s required in 23 patients, mainly because of congestive heart failure.

278 rdiomyopathies, which are a leading cause of congestive heart failure.

279 cular events, peripheral artery disease, and congestive heart failure.

280 fluid retention, weight gain, bone loss and congestive heart failure.

281 al fibrillation, ischemic heart diseases, or congestive heart failure.

282 orrelated with renal dysfunction in advanced congestive heart failure.

283 e consisting of death, reinfarction, and new congestive heart failure.

284 were male; 13% had had a stroke; and 45% had congestive heart failure.

285 Captopril, which is generally used to treat congestive heart failure.

286 ute myocardial infarction and for those with congestive heart failure.

287 nary artery disease, arrhythmias, stroke, or congestive heart failure.

288 prevention of DOX-induced cardiotoxicity and congestive heart failure.

289 -eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein

290 ted with CKD in individual CHA(2)DS(2)-VASc (Congestive heart failure; Hypertension; Age >/=75 years;

291 mprove Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).

292 and systemic right ventricles have premature congestive heart failure; there is also a growing concer

293 o prespecified cardiac events or symptomatic congestive heart failures were reported.

294 We developed a murine experimental model of congestive hepatopathy through partial ligation of the i

295 These studies mechanistically link congestive hepatopathy to hepatic fibrosis.

296 Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; howev

297 n mice after pIVCL as well as in humans with congestive hepatopathy.

298 formations (AVMs) can lead to development of congestive myelopathy (Foix-Alajouanine syndrome).

299 cute to chronic neurological symptoms due to congestive myelopathy caused by intradural spinal AVMs.

300 Right ventricular dysfunction and congestive states may contribute to alterations of renal